Do you want to find out how to take an antibody developed in academia through clinical trials, to be administered in humans?
Dr Dimiter Dimitrov, Head of the Protein Interaction Group at the National Cancer Institute and his group have developed a therapeutic antibody against Hendra and Nipah viruses. The m102.4 was identified and characterised in an academic setting and taken through GMP production with the help of government funding – the first therapeutic of rare viral disease to take this route to patients!
Click here to view the full presentation
Do you want to find out more?